Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$77.90
1.161.51%
al cierre: -
$77.85
-0.05-0.06%
After hour: Oct 10, 7:33 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
CVS Health Corp ha un obiettivo di prezzo di consenso pari a $80.75, stabilito in base alle ultime valutazioni degli analisti di 25. Le ultime 3 valutazioni degli analisti sono state rilasciate da Mizuho, Wells Fargo y Bernstein il octubre 9, 2025, octubre 7, 2025 y septiembre 5, 2025. Con un obiettivo di prezzo medio di $89.33 tra le Mizuho, Wells Fargo y Bernstein, c'è un implicito 14.75% upside per CVS Health Corp da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Mizuho
Wells Fargo
Bernstein
Barclays
Cantor Fitzgerald
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para CVS Health
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/09/2025 | 13.04% | Mizuho | $76 → $88 | Maintains | Outperform | |||
10/07/2025 | 32.31% | Wells Fargo | $84 → $103 | Maintains | Overweight | |||
09/05/2025 | -1.09% | Bernstein | $72 → $77 | Maintains | Market Perform | |||
09/04/2025 | 11.75% | Barclays | $80 → $87 | Maintains | Overweight | |||
08/26/2025 | 0.19% | Cantor Fitzgerald | $78 → $78 | Reiterates | Overweight → Overweight | |||
08/18/2025 | 1.48% | UBS | $67 → $79 | Upgrade | Neutral → Buy | |||
08/14/2025 | 5.33% | Baird | $71 → $82 | Upgrade | Neutral → Outperform | |||
08/01/2025 | 5.33% | Morgan Stanley | $80 → $82 | Maintains | Overweight | |||
08/01/2025 | 2.76% | Barclays | $79 → $80 | Maintains | Overweight | |||
07/22/2025 | -13.94% | UBS | $71 → $67 | Maintains | Neutral | |||
06/30/2025 | 2.76% | Jefferies | $74 → $80 | Maintains | Buy | |||
06/02/2025 | 1.48% | Barclays | $82 → $79 | Maintains | Overweight | |||
05/12/2025 | 7.9% | Truist Securities | $82 → $84 | Maintains | Buy | |||
05/06/2025 | 7.9% | Wells Fargo | $76 → $84 | Maintains | Overweight | |||
05/05/2025 | 4.05% | RBC Capital | $74 → $81 | Maintains | Outperform | |||
05/02/2025 | -8.8% | UBS | $67 → $71 | Maintains | Neutral | |||
05/02/2025 | 5.33% | Barclays | $73 → $82 | Maintains | Overweight | |||
04/15/2025 | -8.8% | Baird | $51 → $71 | Maintains | Neutral | |||
04/11/2025 | 5.33% | Truist Securities | $76 → $82 | Maintains | Buy | |||
04/09/2025 | -2.38% | Mizuho | $70 → $76 | Maintains | Outperform | |||
03/21/2025 | -4.95% | Piper Sandler | $72 → $74 | Maintains | Overweight | |||
02/18/2025 | 4.05% | JP Morgan | $80 → $81 | Maintains | Overweight | |||
02/13/2025 | -6.23% | Wells Fargo | $68 → $73 | Maintains | Overweight | |||
02/13/2025 | -2.38% | Truist Securities | $60 → $76 | Maintains | Buy | |||
02/13/2025 | -6.23% | Barclays | $71 → $73 | Maintains | Overweight | |||
02/13/2025 | -3.66% | Leerink Partners | $55 → $75 | Upgrade | Market Perform → Outperform | |||
01/27/2025 | -16.51% | Evercore ISI Group | $60 → $65 | Maintains | Outperform | |||
01/06/2025 | -22.93% | Truist Securities | $67 → $60 | Maintains | Buy | |||
12/03/2024 | -15.22% | Deutsche Bank | $66 → $66 | Upgrade | Hold → Buy | |||
11/25/2024 | 2.76% | TD Cowen | $73 → $80 | Maintains | Buy | |||
11/25/2024 | -17.79% | Piper Sandler | $72 → $64 | Maintains | Overweight | |||
11/20/2024 | -13.94% | Truist Securities | $76 → $67 | Reiterates | Buy → Buy | |||
11/18/2024 | -15.22% | Wells Fargo | $60 → $66 | Upgrade | Equal-Weight → Overweight | |||
11/15/2024 | -25.5% | RBC Capital | $68 → $58 | Maintains | Outperform | |||
11/07/2024 | -20.36% | UBS | $60 → $62 | Maintains | Neutral | |||
11/07/2024 | -8.8% | Barclays | $75 → $71 | Maintains | Overweight | |||
11/04/2024 | -22.93% | Wells Fargo | $61 → $60 | Maintains | Equal-Weight | |||
10/24/2024 | -15.22% | Mizuho | $73 → $66 | Maintains | Outperform | |||
10/23/2024 | -3.66% | Barclays | $82 → $75 | Maintains | Overweight | |||
10/11/2024 | -2.38% | Truist Securities | $66 → $76 | Maintains | Buy | |||
10/10/2024 | 5.33% | Barclays | $63 → $82 | Upgrade | Equal-Weight → Overweight | |||
10/08/2024 | -3.66% | Evercore ISI Group | $62 → $75 | Maintains | Outperform | |||
10/04/2024 | 9.18% | TD Cowen | $59 → $85 | Upgrade | Hold → Buy | |||
10/01/2024 | -20.36% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/16/2024 | -20.36% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/10/2024 | -20.36% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/04/2024 | -12.65% | RBC Capital | $68 → $68 | Reiterates | Outperform → Outperform | |||
08/19/2024 | -20.36% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
08/12/2024 | -21.64% | Wells Fargo | $60 → $61 | Maintains | Equal-Weight | |||
08/09/2024 | -19.08% | Deutsche Bank | $64 → $63 | Maintains | Hold | |||
08/08/2024 | -19.08% | Barclays | $65 → $63 | Maintains | Equal-Weight | |||
08/08/2024 | -20.36% | Cantor Fitzgerald | $58 → $62 | Maintains | Neutral | |||
08/08/2024 | -20.36% | Evercore ISI Group | $65 → $62 | Maintains | Outperform | |||
07/23/2024 | -25.5% | Cantor Fitzgerald | $58 → $58 | Reiterates | Neutral → Neutral | |||
06/12/2024 | -25.5% | Cantor Fitzgerald | $58 → $58 | Reiterates | Neutral → Neutral | |||
05/30/2024 | 10.47% | JP Morgan | $101 → $86 | Maintains | Overweight | |||
05/30/2024 | -21.64% | Baird | → $61 | Initiates | → Neutral | |||
05/08/2024 | 2.76% | Argus Research | $100 → $80 | Maintains | Buy | |||
05/07/2024 | -22.93% | Wells Fargo | $76 → $60 | Maintains | Equal-Weight | |||
05/07/2024 | -24.21% | TD Cowen | $99 → $59 | Downgrade | Buy → Hold | |||
05/02/2024 | -1.09% | B of A Securities | $95 → $77 | Maintains | Buy | |||
05/02/2024 | -4.95% | Goldman Sachs | $85 → $74 | Maintains | Buy | |||
05/02/2024 | -19.08% | Barclays | $78 → $63 | Maintains | Equal-Weight | |||
05/02/2024 | -22.93% | UBS | $85 → $60 | Downgrade | Buy → Neutral | |||
05/02/2024 | -15.22% | Truist Securities | $90 → $66 | Reiterates | Buy → Buy | |||
05/02/2024 | -7.51% | Mizuho | $86 → $72 | Maintains | Buy | |||
05/01/2024 | -22.93% | Leerink Partners | → $60 | Downgrade | Outperform → Market Perform | |||
05/01/2024 | -25.5% | Cantor Fitzgerald | $87 → $58 | Downgrade | Overweight → Neutral | |||
04/10/2024 | 11.75% | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
04/08/2024 | -2.38% | Wells Fargo | $83 → $76 | Maintains | Equal-Weight | |||
04/04/2024 | 11.75% | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
03/15/2024 | 20.75% | Piper Sandler | $93 → $94 | Maintains | Overweight | |||
03/06/2024 | 0.19% | Barclays | → $78 | Initiates | → Equal-Weight | |||
02/26/2024 | 13.04% | Leerink Partners | → $88 | Initiates | → Outperform | |||
02/08/2024 | 11.75% | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
02/08/2024 | 7.9% | RBC Capital | $86 → $84 | Maintains | Outperform | |||
12/22/2023 | 20.75% | HSBC | → $94 | Initiates | → Buy | |||
12/11/2023 | 27.17% | TD Cowen | $102 → $99 | Maintains | Outperform | |||
11/21/2023 | 11.75% | Cantor Fitzgerald | → $87 | Reiterates | Overweight → Overweight | |||
11/02/2023 | 10.47% | Mizuho | $88 → $86 | Maintains | Buy | |||
11/02/2023 | 10.47% | RBC Capital | $91 → $86 | Maintains | Outperform | |||
11/02/2023 | 28.45% | Morgan Stanley | $110 → $100 | Maintains | Overweight | |||
09/19/2023 | 6.62% | Evercore ISI Group | $81 → $83 | Upgrade | In-Line → Outperform | |||
09/14/2023 | 11.75% | Cantor Fitzgerald | → $87 | Reiterates | Overweight → Overweight | |||
09/12/2023 | 2.76% | Wolfe Research | → $80 | Upgrade | Peer Perform → Outperform | |||
09/01/2023 | 5.33% | Piper Sandler | $85 → $82 | Maintains | Overweight | |||
08/18/2023 | 16.89% | RBC Capital | → $91 | Reiterates | Outperform → Outperform | |||
08/18/2023 | — | Edward Jones | — | Downgrade | Buy → Hold | |||
08/04/2023 | 9.18% | Raymond James | $90 → $85 | Maintains | Outperform | |||
08/03/2023 | 25.88% | Truist Securities | $103 → $98 | Maintains | Buy | |||
08/03/2023 | 41.3% | Morgan Stanley | $120 → $110 | Maintains | Overweight | |||
08/03/2023 | 16.89% | RBC Capital | $102 → $91 | Maintains | Outperform | |||
08/03/2023 | 10.47% | Barclays | $89 → $86 | Maintains | Overweight | |||
07/12/2023 | 14.32% | Barclays | $90 → $89 | Maintains | Overweight | |||
07/11/2023 | 13.04% | Mizuho | $120 → $88 | Maintains | Buy | |||
07/07/2023 | 36.16% | JP Morgan | $114 → $106 | Maintains | Overweight | |||
06/20/2023 | 32.31% | Truist Securities | $109 → $103 | Maintains | Buy | |||
05/30/2023 | 46.44% | JP Morgan | $125 → $114 | Maintains | Overweight | |||
05/26/2023 | 9.18% | Piper Sandler | → $85 | Initiates | → Overweight | |||
05/09/2023 | 31.02% | RBC Capital | → $102 | Reiterates | → Outperform |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de CVS Health (CVS)?
El último precio objetivo de CVS Health (NYSE:CVS) fue comunicado por Mizuho el octubre 9, 2025. La firma de analistas fijó un precio objetivo para $88.00 que espera CVS a rise dentro de 12 meses (un posible 13.04% upside). 39 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre CVS Health (CVS)?
La última calificación de analistas para CVS Health (NYSE:CVS) fue proporcionada por Mizuho, y CVS Health mantuvo su outperform calificación.
¿Cuándo se produjo la última revisión al alza de CVS Health (CVS)?
La última revisión al alza de CVS Health Corp se produjo en agosto 18, 2025, cuando UBS elevó su precio objetivo a $79. UBS anteriormente tenía a neutral para CVS Health Corp.
¿Cuándo fue la última revisión a la baja de CVS Health (CVS)?
La última revisión a la baja de CVS Health Corp se produjo en mayo 7, 2024, cuando TD Cowen cambió su precio objetivo de $99 a $59 para CVS Health Corp.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para CVS Health (CVS)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de CVS Health, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de CVS Health se registró el octubre 9, 2025, por lo que la próxima calificación estará disponible en torno al octubre 9, 2026.
¿Es correcta la calificación de los analistas sobre CVS Health (CVS)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de CVS Health (CVS) fue un mantuvo con un precio objetivo de $76.00 a $88.00. El precio actual al que cotiza CVS Health (CVS) es de $77.85, que es within del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.